Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients.
Identifieur interne : 003928 ( Main/Exploration ); précédent : 003927; suivant : 003929Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients.
Auteurs : RBID : pubmed:10916113English descriptors
- KwdEn :
- Adult, Aged, Amyloidosis (radionuclide imaging), Female, Humans, Indium Radioisotopes (diagnostic use), Kidney Failure, Chronic (radionuclide imaging), Kidney Failure, Chronic (therapy), Male, Middle Aged, Radiation Dosage, Radionuclide Imaging (methods), Recombinant Proteins (diagnostic use), Renal Dialysis, Sensitivity and Specificity, Uremia (radionuclide imaging), Uremia (therapy), beta 2-Microglobulin (diagnostic use).
- MESH :
- chemical , diagnostic use : Indium Radioisotopes, Recombinant Proteins, beta 2-Microglobulin.
- methods : Radionuclide Imaging.
- radionuclide imaging : Amyloidosis, Kidney Failure, Chronic, Uremia.
- therapy : Kidney Failure, Chronic, Uremia.
- Adult, Aged, Female, Humans, Male, Middle Aged, Radiation Dosage, Renal Dialysis, Sensitivity and Specificity.
Abstract
We previously introduced scintigraphy with 131I-labeled beta2-microglobulin (beta2m), purified from uremic hemofiltrate, that is, "natural" beta2m, to specifically detect beta2m-associated amyloidosis (Abeta2m) in hemodialysis (HD) patients.
DOI: 10.1046/j.1523-1755.2000.00237.x
PubMed: 10916113
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients.</title><author><name sortKey="Sch Ffer, J" uniqKey="Sch Ffer J">J Schäffer</name><affiliation wicri:level="3"><nlm:affiliation>Divisions of Nephrology and Nuclear Medicine, Medical School, Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Divisions of Nephrology and Nuclear Medicine, Medical School, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Burchert, W" uniqKey="Burchert W">W Burchert</name></author><author><name sortKey="Floege, J" uniqKey="Floege J">J Floege</name></author><author><name sortKey="Gielow, P" uniqKey="Gielow P">P Gielow</name></author><author><name sortKey="Kionka, C" uniqKey="Kionka C">C Kionka</name></author><author><name sortKey="Linke, R P" uniqKey="Linke R">R P Linke</name></author><author><name sortKey="Weiss, E H" uniqKey="Weiss E">E H Weiss</name></author><author><name sortKey="Shaldon, S" uniqKey="Shaldon S">S Shaldon</name></author><author><name sortKey="Koch, K M" uniqKey="Koch K">K M Koch</name></author></titleStmt><publicationStmt><date when="2000">2000</date><idno type="RBID">pubmed:10916113</idno><idno type="pmid">10916113</idno><idno type="doi">10.1046/j.1523-1755.2000.00237.x</idno><idno type="wicri:Area/Main/Corpus">003C30</idno><idno type="wicri:Area/Main/Curation">003C30</idno><idno type="wicri:Area/Main/Exploration">003928</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Amyloidosis (radionuclide imaging)</term><term>Female</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Kidney Failure, Chronic (radionuclide imaging)</term><term>Kidney Failure, Chronic (therapy)</term><term>Male</term><term>Middle Aged</term><term>Radiation Dosage</term><term>Radionuclide Imaging (methods)</term><term>Recombinant Proteins (diagnostic use)</term><term>Renal Dialysis</term><term>Sensitivity and Specificity</term><term>Uremia (radionuclide imaging)</term><term>Uremia (therapy)</term><term>beta 2-Microglobulin (diagnostic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Recombinant Proteins</term><term>beta 2-Microglobulin</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radionuclide Imaging</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Amyloidosis</term><term>Kidney Failure, Chronic</term><term>Uremia</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Kidney Failure, Chronic</term><term>Uremia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Radiation Dosage</term><term>Renal Dialysis</term><term>Sensitivity and Specificity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We previously introduced scintigraphy with 131I-labeled beta2-microglobulin (beta2m), purified from uremic hemofiltrate, that is, "natural" beta2m, to specifically detect beta2m-associated amyloidosis (Abeta2m) in hemodialysis (HD) patients.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">10916113</PMID><DateCreated><Year>2000</Year><Month>09</Month><Day>07</Day></DateCreated><DateCompleted><Year>2000</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0085-2538</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>2</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Kidney international</Title><ISOAbbreviation>Kidney Int.</ISOAbbreviation></Journal><ArticleTitle>Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients.</ArticleTitle><Pagination><MedlinePgn>873-80</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We previously introduced scintigraphy with 131I-labeled beta2-microglobulin (beta2m), purified from uremic hemofiltrate, that is, "natural" beta2m, to specifically detect beta2m-associated amyloidosis (Abeta2m) in hemodialysis (HD) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To improve the safety and resolution of the scan, we covalently bound the chelator diethylenetriaminepentaacetic acid to natural beta2m to allow radiolabeling with 111In. In a second step, we generated and evaluated the usage of recombinant human beta2m (rhbeta2m) for scintigraphy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Using natural 111In-labeled beta2m, eight patients on HD for 0 to 17 years, without evidence of Abeta2m, were scanned. Whole-body scintigraphy at 48 to 72 hours postinjection revealed no significant tracer accumulation over joint regions. In contrast, nine patients on HD for 10 to 21 years with clinical, radiological, or histologic (N = 4) evidence of Abeta2m showed selective tracer uptake over various joint regions. Tracer accumulation in visceral organs, which could not be related to tracer elimination or metabolism, was not detected. Compared with the previous 131I beta2m scan, scintigraphy with 111In-labeled beta2m offered highly improved image contrast, increased sensitivity, and a 50 to 70% reduction of the radiation exposure. Scanning with 111In-labeled recombinant human beta2m was performed in six patients: No significant tracer accumulation was observed over joint regions in two patients on short-term HD without evidence of Abeta2m; in contrast, local tracer accumulations similar to those observed with natural beta2m could be demonstrated in four long-term (10 to 27 years) HD patients with clinical, radiological, and histologic (N = 1) evidence of Abeta2m.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Scintigraphy for Abeta2m with 111In-labeled rhbeta2m provides a homogenous and safe recombinant protein source and leads to enhanced sensitivity and lower radiation exposure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schäffer</LastName><ForeName>J</ForeName><Initials>J</Initials><Affiliation>Divisions of Nephrology and Nuclear Medicine, Medical School, Hannover, Germany.</Affiliation></Author><Author ValidYN="Y"><LastName>Burchert</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Floege</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gielow</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kionka</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Linke</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Shaldon</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Comparative Study</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Kidney Int</MedlineTA><NlmUniqueID>0323470</NlmUniqueID><ISSNLinking>0085-2538</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>beta 2-Microglobulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Kidney Failure, Chronic</DescriptorName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiation Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radionuclide Imaging</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Renal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Uremia</DescriptorName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">beta 2-Microglobulin</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>1</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10916113</ArticleId><ArticleId IdType="pii">kid237</ArticleId><ArticleId IdType="doi">10.1046/j.1523-1755.2000.00237.x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003928 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003928 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:10916113
|texte= Recombinant versus natural human 111In-beta2-microglobulin for scintigraphic detection of Abeta2m amyloid in dialysis patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:10916113" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |